Sacituzumab Tirumotecan Improves PFS in Advanced NSCLC
A phase 3 trial found sacituzumab tirumotecan plus pembrolizumab improved progression-free outcomes in first-line PD-L1-positive advanced NSCLC, while survival and safety data remain immature.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.